Since the completion of my initial training in clinical endocrinology, I have been involved in clinical research. Dissecting the underlying metabolic defects in pathogenesis of T2DM and mechanisms of action of newer anti-diabetic medications has been my field of interest. I have successfully completed numerous NIH and industry funded clinical trials. I am currently involved primarily in metabolic studies in humans which characterize the molecular mechanisms of insulin resistance and beta cell dysfunction in the pathogenesis of diabetes, and the novel mechanism of action of newer anti-diabetic drugs. I have also been actively involved in several large industry sponsored and VA funded multi-center clinical trials which examined the effect of newer anti-diabetic drugs and intensive glycemic control on cardiovascular events in T2DM.